FUNDAMENTALS · Fundamentals · US Healthcare

Sintx Technologies (SINT) Fundamentals 2026 — Revenue Analysis | SniperIQ

Sintx Technologies (SINT) is a US-listed Healthcare company in Medical - Devices with a market capitalization of $4M, trading at

.58 on the NASDAQ. This SniperIQ fundamentals page covers Sintx Technologies's valuation, profitability (net margin -1711.6%), revenue (
M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$4M
Net Margin-1711.6%
Revenue (FY25)
M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Sintx Technologies's market cap?

Sintx Technologies (SINT) has a market capitalization of approximately $4M, trading at

.58 on the NASDAQ. Market cap moves with the live share price.

What is Sintx Technologies's P/E ratio?

Sintx Technologies's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 7.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Sintx Technologies?

Sintx Technologies runs a net profit margin of -1711.6%, a gross margin of -32.7%, and an operating margin of -1122.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Sintx Technologies generate?

Sintx Technologies reported revenue of

M for fiscal year 2025, with net income of -
7M and earnings per share (EPS) of -6.16. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Sintx Technologies pay a dividend?

Sintx Technologies does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Sintx Technologies financially healthy?

Sintx Technologies carries a debt-to-equity ratio of 3.61x and a current ratio of 1.04x, with a market beta of 0.63. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Sintx Technologies a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sintx Technologies (SINT) the key facts are: market cap $4M, revenue

M, 52-week range 1.52-6.78. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Sintx Technologies's full fundamentals live

Get Sintx Technologies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: BioAtla (BCAB) fundamentals · Aprea Therapeutics (APRE) fundamentals · Revelation Biosciences (REVB) fundamentals · Tempest Therapeutics (TPST) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons